NFKB1 and tuberculosis: Anti-tuberculosis drugs activated the TLR4–NF-κB–MyD88 pathway to induce liver injury, and high-dose Lc intervention inhibited the activation of NF-κB and MyD88 proteins, thus reducing oxidative stress and inflammatory response, as well as alleviating liver injury.